Cullinan Therapeutics provided a corporate update and shared anticipated business highlights for 2026, focusing on key developments in their autoimmune and oncology programs.
The company reported progress on multiple dose cohorts in autoimmune studies and the initiation of dosing in Sjögren's disease study.
Key milestones include completion of monotherapy expansion cohorts, initiation of combination studies, and expected NDA submissions and study enrollments.
CLN-978 Data Readouts
Anticipated data readouts planned for CLN-978 across autoimmune indications in 2026, including single dose and repeat dosing data.
CLN-049 Program Advancements
Progress in CLN-049 program with compelling efficacy and safety data, leading to accelerated approval pathway, dose expansions, and frontline combination studies.
Zipalertinib Milestones
Expected completion of NDA submission and enrollment in the REZILIENT3 frontline study for zipalertinib in 2026.
- Cullinan Therapeutics aims to deliver company-sponsored data with a CD19 T cell engager in autoimmune diseases, positioning for significant progress in 2026.
- 2026 marks pivotal milestones across various programs, setting the company on a transformative path with multiple catalysts ahead.
With a focus on advancing T cell engager programs and achieving key milestones, Cullinan Therapeutics prepares for a promising and transformative year in 2026.